This study is looking at dupilumab, an experimental drug, for young children with active eosinophilic esophagitis (EoE), an allergic condition of the esophagus (food pipe) that can affect eating. The study aims to understand how safe, tolerable, and effective dupilumab is when given for 24 weeks. Researchers will also check for side effects, how much of the drug is in the blood, and if the body makes antibodies against the drug. Children aged 6 months to 6 years, weighing 5 to 15 kg, with active EoE and symptoms in the month before screening, may be able to join. The main goal is to track any serious side effects that happen during the first 24 weeks.

Study design

This is an interventional study planning to enroll 20 participants. The phase of the study is not specified.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

The study will track serious side effects for up to 24 weeks after treatment begins.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.